Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011570 (
depression
)
172,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A group of patients with both
depression
and chronic pain were treated with doxepin for 4 weeks. Elevated (above median) initial levels of urinary 3-methoxy-4-hydroxyphenethylene glycol (
MHPG
, a metabolite of central nervous system [CNS] norepinephrine metabolism) were found to be significantly related to final pain relief, but not to improvement in
depression
. Anxiety, as measured on the Zung Anxiety Scale, was an important covariable, as high anxiety levels were significantly associated with both higher
MHPG
levels and with pain relief. Possible biochemical and psychophysiological mechanisms associated with the modulation of pain are discussed.
...
PMID:Urinary 3-methoxy-4-hydroxyphenethylene glycol in the prediction of pain and depression relief with doxepin: preliminary findings. 684 50
A 38-year old woman with a bipolar affective disorder was examined for 10 days during a serious retarded
depression
phase and for 10 days during the subsequent symptom -free interval. During
depression
the
MHPG
-excretion showed a significantly shorter circadian periodicity of 20.5 hours, whereas the periodicity of body temperature and VMA amounted to 24 hours. During the symptom-free interval the circadian periodicity of all parameters was 24 hours. These results indicated that the
depression
phase of a bipolar affective disorder in this patient is related to a desynchronization of central NA function with peripheral NA activity and body temperature.
...
PMID:Circadian course of body temperature and the excretion of MHPG and VMA in a patient with bipolar depression. 707 17
Stressful procedures are reported to increase urinary
MHPG
in both normal and depressed patients. Bipolar depressed patients are also shown to be especially pain tolerant in comparison to normals. In the present study, 12 depressed patients (6 bipolar and 6 unipolar patients) and 10 normal volunteers had average evoked potentials recorded for visual and painful electrical stimuli.
MHPG
urinary excretion was measured during this session and during an unstimulated resting session on the home ward. Male normal volunteers showed a significant increase in urinary
MHPG
under stress, while no
MHPG
increment was noted for the depressed group. Depth of
depression
, assessed by the Zung and Beck scales, was found to be correlated with the reduced urinary
MHPG
response to stress. Possible interpretations of the results are discussed.
...
PMID:Urinary MHPG, stress response, personality factors and somatosensory evoked potentials in normal subjects and patients with major affective disorders. 719 13
Twenty-two patients with primary anorexia nervosa were assessed on variables of weight, mood, dexamethasone suppression test, and 24-hour urinary
MHPG
levels. Patients at less than 80% of their ideal weight had abnormally high cortisol levels after the test and low
MHPG
levels, regardless of their mood. The authors hypothesize that these abnormalities are not due to
depression
associated with anorexia nervosa and that decreased norepinephrine metabolism may be related to this illness.
...
PMID:Abnormalities of dexamethasone suppression test and urinary MHPG in anorexia nervosa. 723 62
A 5-day study, forming the initial part of two 32-day clinical trials and involving 22 unipolar depressed inpatients, was designed to determine the relationship between response to sleep deprivation and 24-hour urinary
MHPG
levels. A statistically significant, positive relationship was noted between the sleep deprivation, modified total HAM-D scores and
MHPG
levels at postsleep deprivation, indicating that the greater the severity of
depression
during sleep deprivation the higher were the
MHPG
levels after the sleep deprivation period.
...
PMID:Relationship between sleep deprivation and urinary MHPG levels. 744 97
The serotonin uptake inhibitor fluvoxamine was assessed in treatment of alcohol-induced Korsakoff's syndrome (KS) using fixed (4 weeks, 200 mg/day) or individualized (6 weeks, plasma concentration > or = 400 ng/ml) dosing in randomized placebo-controlled double-blind crossover studies. Cognitive functions and concentrations of the major cerebrospinal fluid (CSF) metabolites of serotonin (5-HIAA), norepinephrine (
MHPG
), and dopamine (HVA) were determined in abstinent, nondepressed KS patients (aged 45-75), at baseline and placebo (3-4 weeks), and after 3-4 (n = 10) or 6 (n = 4) weeks of fluvoxamine administration. Fluvoxamine decreased CSF 5-HIAA compared to placebo (P < 0.003) without consistent changes in HVA or
MHPG
. Reductions in 5-HIAA correlated with improvements on the Wechsler Memory Scale Memory Quotient (P < 0.05), independent of effects on attention/vigilance or Beck
Depression
Inventory scores. Reductions in 5-HIAA correlated with plasma fluvoxamine (P < 0.03) only for fluvoxamine concentrations below 450 ng/ml. These findings suggest improvement of memory consolidation and/or retrieval in patients with Korsakoff's syndrome by fluvoxamine via serotonergic mechanisms.
...
PMID:Fluvoxamine treatment of alcoholic amnestic disorder. 754 52
This study evaluated diurnal data gathered hourly (1000 to 1800 hours) in males during acute
depression
and during remission of
depression
and in age-range/gender-matched normal controls. Mean, peak, variability, and time-course of the noradrenergic metabolite, plasma 3-methoxy, 4-hydroxyphenylglycol [
MHPG
]), plasma cortisol, and autonomic (mean arterial blood pressure [MAP] and heart rate) variables were examined. Compared to controls, acutely depressed, but not remitted depressed, patients had 1) an earlier plasma
MHPG
peak, 2) a greater intragroup variability of plasma
MHPG
, 3) a higher plasma cortisol concentration, 4) a lower MAP, and 5) tended to increase MAP more slowly than did the normal controls. The time course of diurnal heart rate also differed in acutely depressed patients from controls: acutely depressed patients started higher and converged by midday to normal levels. These diurnal data lend limited support to the dysregulation hypotheses of
depression
that suggest normal circadian rhythmicities are altered or disrupted in acute
depression
and that peripheral manifestations of central dysregulation normalize in remission of
depression
.
...
PMID:Diurnal neuroendocrine and autonomic function in acute and remitted depressed male patients. 778 58
BW 1370U87 is unique among potent inhibitors of monoamine oxidase-A (MAO-A) in that it contains no nitrogen. Like other MAO-A inhibitors, BW 1370U87 elevates neurotransmitter amines in the brain over the same dose range at which it exhibits positive activities in animal models of depressive illness. However, BW 1370U87 differs from most other MAO inhibitors in that its mechanism of action follows simple competitive kinetics, so that an unusually high concentration of tyramine in peripheral tissues may displace the inhibitor from MAO-A sites in the intestine and liver. In addition, BW 1370U87 concentrations in brains of rats appear much higher than in plasma, whereas extensive metabolism of the parent compound in the liver produces weaker MAO-A inhibitors with the same type of competitive mechanism. Early phase-I safety trials at acute doses up to 2,000 mg of BW 1370U87 showed no adverse reactions, whereas
MHPG
in urine was decreased, indicating that in vivo inhibition of MAO-A was achieved in humans. Thus BW 1370U87 represents a new agent with potential therapeutic application in
depression
and other CNS illnesses.
...
PMID:Preclinical and early clinical studies with BW 1370U87, a reversible competitive monoamine oxidase-A inhibitor. 831 94
To elucidate the influence of total sleep deprivation (TSD) on catecholaminergic neurotransmission, which is assumed to be disturbed in
depression
, 9 depressive patients collected consecutive 24-h urine samples prior to (baseline), during (TSD) and following total sleep deprivation (post-TSD). Urine samples were analysed for total
MHPG
(3-methoxy-4-hydroxyphenylglycol), conjugates of
MHPG
(glucuronide and sulfate), excretion of HVA (homovanillic acid) and VMA (3-methoxy-4-hydroxymandelic acid). TSD increased the urinary excretion of MHPG-sulfate as a marker of the central norepinephrine metabolism and the excretion rates of VMA and HVA as indices of the peripheral catecholamine metabolism. Patients with higher VMA values prior to TSD reacted worse, and the VMA increase due to TSD was positively correlated with the response. The results demonstrate that TSD, besides acting as a stimulus on the peripheral sympathetic nervous system, influences central nervous noradrenergic neurotransmission, as reflected by the increase of MHPG-sulfate.
...
PMID:The influence of total sleep deprivation on urinary excretion of catecholamine metabolites in major depression. 839 44
This report was undertaken to test the noradrenergic deficiency hypothesis of
depression
and the postulated increase in noradrenergic activity associated to anxiety states. A possible dual effect of both
depression
and anxiety on total plasma
MHPG
levels was hypothesized and assessed in anxious and non-anxious depressed patients. The findings show a decrease in plasma
MHPG
levels in depressed patients whatever their degree of anxiety. There was no difference in total plasma
MHPG
levels either between anxious and non-anxious depressed patients or between low and high anxiety to
depression
ratio (ADR) depressed patients. Following antidepressant drug-treatment, a decrease in plasma
MHPG
was found. A positive correlation between the drug-induced decrease in NA activity and the severity of
depression
was observed, and suggested a relationship between the severity of
depression
and the instability of the NA system. No correlation between the drug-induced decrease in plasma
MHPG
and the degree of anxiety was found. The results do not suggest out an effect of anxiety on total plasma
MHPG
levels in depressed patients.
...
PMID:Lack of effect of anxiety on total plasma MHPG in depressed patients. 840 83
<< Previous
1
2
3
4
5
6
7
8
Next >>